36C26326N0312↗
Exelan Pharmaceuticals Inc received this contract from Network Contract Office 23 (36C263), Department of Veterans Affairs: $2.30M obligated so far for drugs and biologicals. It runs to 2026-12-31.
Key facts · data as of Oct 23, 2026
- Recipient
- Exelan Pharmaceuticals Inc
- Awarding agency
- Department of Veterans Affairs
- Contracting office
- Network Contract Office 23 (36C263) (36C263)
- Obligated to date
- $2.30M
- Potential value
- $2.30M
- Ends
- 2026-12-31
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 23, 2026.
Cite this page: SpendQuery, Award 36C26326N0312, data as of Oct 23, 2026, https://spendquery.com/award?id=CONT_AWD_36C26326N0312_3600_36F79720D0227_3600
Exelan Pharmaceuticals Inc: all federal awards · Department of Veterans Affairs: spending · Network Contract Office 23 (36C263): what it buys · The follow-on: recompete brief
GENERIC LENALIDOMIDE DRUG
Up for re-bid: ends 2026-12-31. Recompete brief →
What it is
- Product or service
- Drugs and Biologicals (PSC 6505)
- Industry
- Pharmaceutical Preparation Manufacturing (NAICS 325412)
- Contracting office
- Network Contract Office 23 (36C263) (36C263)
- Competition
- Full and open competition · 2 offers received
- Pricing
- Firm fixed price
- How it was bought
- GSA Schedule · under 36F79720D0227
- Where the work is
- Palm Beach, FL · district FL-23
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
3 actions since 2025-12-29. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-09-16 | P00002 | Supplemental agreement (work within scope) | -$274.9K | GENERIC LENALIDOMIDE DRUG |
| 2026-06-24 | P00001 | Supplemental agreement (work within scope) | -$840.1K | GENERIC LENALIDOMIDE DRUG |
| 2025-12-29 | 0 | $3.42M | GENERIC LENALIDOMIDE DRUG |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-23). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗